Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia
ConditionHyponatremia
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.
Eligibility criteria
Qualifiers
Adults ( ≥18 years)
Current admission in ICU
Severe hyponatremia defined by SNa <120 mmol/L in the presence of neurological symptoms (seizures, stupor defined as Glasgow score < 12, or signs of brain herniation) or by SNa <115 mmol/L
Normal or decreased extracellular fluid volume
Disqualifiers
Obvious increase of extracellular fluid volume (cirrhosis with ascites, congestive heart failure, nephrotic syndrome);
Hyponatremia caused by hyperglycaemia (> 30 mmol/L) or hypertriglyceridemia (10 g/L) or hyperproteinaemia (120 g/L)
Severe acute kidney injury (KDIGO 3)
Severe chronic kidney disease (eGFR <20 ml/min)
Trial design
Treatments tested in this trial
- DDAVP
- Standard hyponatremia treatment
Treatment groups
260 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov